Cargando…

History of Innate Immunity in Neurodegenerative Disorders

The foundations of innate immunity in neurodegenerative disorders were first laid by Del Rio Hortega (1919). He identified and named microglia, recognizing them as cells of mesodermal origin. Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as the brain representatives. Val...

Descripción completa

Detalles Bibliográficos
Autores principales: McGeer, Patrick L., McGeer, Edith G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228970/
https://www.ncbi.nlm.nih.gov/pubmed/22144960
http://dx.doi.org/10.3389/fphar.2011.00077
_version_ 1782217894292094976
author McGeer, Patrick L.
McGeer, Edith G.
author_facet McGeer, Patrick L.
McGeer, Edith G.
author_sort McGeer, Patrick L.
collection PubMed
description The foundations of innate immunity in neurodegenerative disorders were first laid by Del Rio Hortega (1919). He identified and named microglia, recognizing them as cells of mesodermal origin. Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as the brain representatives. Validation of these concepts did not occur until 1987 when HLA-DR was identified on activated microglia in a spectrum of neurological disorders. HLA-DR had already been established as a definitive marker of immunocompetent cells of mesodermal origin. It was soon determined that the observed inflammatory reaction was an innate immune response. A rapid expansion of the field took place as other markers of an innate immune response were found that were made by neurons, astrocytes, oligodendroglia, and endothelial cells. The molecules included complement proteins and their regulators, inflammatory cytokines, chemokines, acute phase reactants, prostaglandins, proteases, protease inhibitors, coagulation factors, fibrinolytic factors, anaphylatoxins, integrins, free radical generators, and other unidentified neurotoxins. The Nimmerjahn movies demonstrated that resting microglia were constantly active, sampling the surround, and responding rapidly to brain damage. Ways of reducing the neurotoxic innate immune response and stimulating a healing response continue to be sought as a means for ameliorating the pathology in a spectrum of chronic degenerative disorders.
format Online
Article
Text
id pubmed-3228970
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-32289702011-12-05 History of Innate Immunity in Neurodegenerative Disorders McGeer, Patrick L. McGeer, Edith G. Front Pharmacol Pharmacology The foundations of innate immunity in neurodegenerative disorders were first laid by Del Rio Hortega (1919). He identified and named microglia, recognizing them as cells of mesodermal origin. Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as the brain representatives. Validation of these concepts did not occur until 1987 when HLA-DR was identified on activated microglia in a spectrum of neurological disorders. HLA-DR had already been established as a definitive marker of immunocompetent cells of mesodermal origin. It was soon determined that the observed inflammatory reaction was an innate immune response. A rapid expansion of the field took place as other markers of an innate immune response were found that were made by neurons, astrocytes, oligodendroglia, and endothelial cells. The molecules included complement proteins and their regulators, inflammatory cytokines, chemokines, acute phase reactants, prostaglandins, proteases, protease inhibitors, coagulation factors, fibrinolytic factors, anaphylatoxins, integrins, free radical generators, and other unidentified neurotoxins. The Nimmerjahn movies demonstrated that resting microglia were constantly active, sampling the surround, and responding rapidly to brain damage. Ways of reducing the neurotoxic innate immune response and stimulating a healing response continue to be sought as a means for ameliorating the pathology in a spectrum of chronic degenerative disorders. Frontiers Research Foundation 2011-12-02 /pmc/articles/PMC3228970/ /pubmed/22144960 http://dx.doi.org/10.3389/fphar.2011.00077 Text en Copyright © 2011 McGeer and McGeer. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Pharmacology
McGeer, Patrick L.
McGeer, Edith G.
History of Innate Immunity in Neurodegenerative Disorders
title History of Innate Immunity in Neurodegenerative Disorders
title_full History of Innate Immunity in Neurodegenerative Disorders
title_fullStr History of Innate Immunity in Neurodegenerative Disorders
title_full_unstemmed History of Innate Immunity in Neurodegenerative Disorders
title_short History of Innate Immunity in Neurodegenerative Disorders
title_sort history of innate immunity in neurodegenerative disorders
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228970/
https://www.ncbi.nlm.nih.gov/pubmed/22144960
http://dx.doi.org/10.3389/fphar.2011.00077
work_keys_str_mv AT mcgeerpatrickl historyofinnateimmunityinneurodegenerativedisorders
AT mcgeeredithg historyofinnateimmunityinneurodegenerativedisorders